PL2657248T3 - Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie - Google Patents

Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie

Info

Publication number: PL2657248T3
Authority: PL; Poland
Prior art keywords: uses therefor; aav virions; decreased immunoreactivity; immunoreactivity; decreased
Prior art date: 2003-06-19

Application number

PL13163182T

Other languages

English (en)

Inventor

Alejandra Elena Arbetman

Peter C. Colosi

Michael A. Lochrie

Richard T. Surosky

Original Assignee

Genzyme Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-19

Filing date

2004-06-21

Publication date

2017-09-29

2004-06-21 Application filed by Genzyme Corporation filed Critical Genzyme Corporation

2017-09-29 Publication of PL2657248T3 publication Critical patent/PL2657248T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14161—Methods of inactivation or attenuation
- C12N2750/14162—Methods of inactivation or attenuation by genetic engineering
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Hematology (AREA)
Virology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Cardiology (AREA)
Neurology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)

PL13163182T 2003-06-19 2004-06-21 Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie PL2657248T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US48039503P	2003-06-19	2003-06-19
US56731004P	2004-04-30	2004-04-30
US57650104P	2004-06-03	2004-06-03

Publications (1)

Publication Number	Publication Date
PL2657248T3 true PL2657248T3 (pl)	2017-09-29

Family

ID=33545345

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
PL11158742T PL2357189T3 (pl)	2003-06-19	2004-06-21	Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
PL17162137T PL3235827T3 (pl)	2003-06-19	2004-06-21	Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowania
PL04755800.2T PL1633772T3 (pl)	2003-06-19	2004-06-21	Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
PL13163182T PL2657248T3 (pl)	2003-06-19	2004-06-21	Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
PL13163168T PL2657247T3 (pl)	2003-06-19	2004-06-21	Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
PL11158742T PL2357189T3 (pl)	2003-06-19	2004-06-21	Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
PL17162137T PL3235827T3 (pl)	2003-06-19	2004-06-21	Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowania
PL04755800.2T PL1633772T3 (pl)	2003-06-19	2004-06-21	Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL13163168T PL2657247T3 (pl)	2003-06-19	2004-06-21	Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie

Country Status (11)

Country	Link
US (6)	US7259151B2 (pl)
EP (5)	EP2357189B1 (pl)
JP (7)	JP2007524386A (pl)
CY (5)	CY1117575T1 (pl)
DK (5)	DK3235827T3 (pl)
ES (5)	ES2629087T3 (pl)
HU (5)	HUE054046T2 (pl)
PL (5)	PL2357189T3 (pl)
PT (5)	PT1633772E (pl)
SI (5)	SI2657248T1 (pl)
WO (1)	WO2004112727A2 (pl)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0932694A2 (en)	1996-09-11	1999-08-04	THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Aav4 vector and uses thereof
DE69939169D1 (de)	1998-05-28	2008-09-04	Us Gov Health & Human Serv	Aav5 vektoren und deren verwendung
AU782966B2 (en)	1999-06-08	2005-09-15	University Of Iowa Research Foundation, The	Compounds and methods to enhance RAAV transduction
ES2455126T3 (es)	2001-11-13	2014-04-14	The Trustees Of The University Of Pennsylvania	Secuencias Cy.5 de virus adeno-asociados (AAV), vectores que las contienen y uso de las mismas.
US7419817B2 (en)	2002-05-17	2008-09-02	The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih.	Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
EP1608410A2 (en)	2003-03-31	2005-12-28	University of Iowa Research Foundation	Pharmico-gene theraphy of epithelial sodium channel associated disoders
WO2005017101A2 (en)	2003-05-19	2005-02-24	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH	Avian adenoassociated virus (aaav) and uses thereof
DK3235827T3 (da)	2003-06-19	2021-04-19	Genzyme Corp	Aav-virioner med reduceret immunreaktivitet og anvendelser deraf
US9233131B2 (en) *	2003-06-30	2016-01-12	The Regents Of The University Of California	Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en)	2003-06-30	2016-09-13	The Regents Of The University Of California	Mutant adeno-associated virus virions and methods of use thereof
US8137960B2 (en)	2003-12-04	2012-03-20	The United States Of America As Represented By The Department Of Health And Human Services	Bovine adeno-associated viral (BAAV) vector and uses thereof
US20080188431A1 (en) *	2004-09-08	2008-08-07	Chiorini John A	Transcytosis of Adeno-Associated Viruses
US7892809B2 (en) *	2004-12-15	2011-02-22	The University Of North Carolina At Chapel Hill	Chimeric vectors
ES2434723T3 (es) *	2005-04-07	2013-12-17	The Trustees Of The University Of Pennsylvania	Método de incremento de la función de un vector AAV
US8283151B2 (en)	2005-04-29	2012-10-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
EP2019964A2 (en) *	2006-04-28	2009-02-04	University of Iowa Research Foundation	Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection. method to identify a viral receptor or co-receptor
EP2019143A1 (en)	2007-07-23	2009-01-28	Genethon	CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en)	2007-10-05	2009-05-13	Genethon	Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
ES2429142T3 (es)	2009-01-30	2013-11-13	Uniqure Ip B.V.	Agentes terapéuticos de alanina-glioxilato aminotransferasa
WO2010093784A2 (en)	2009-02-11	2010-08-19	The University Of North Carolina At Chapel Hill	Modified virus vectors and methods of making and using the same
CN102448501A (zh)	2009-03-27	2012-05-09	西马生物医学计划公司	治疗肝硬化和肝纤维化的方法和组合物
EP2287323A1 (en)	2009-07-31	2011-02-23	Association Institut de Myologie	Widespread gene delivery to the retina using systemic administration of AAV vectors
WO2011032100A1 (en)	2009-09-11	2011-03-17	Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Inhibitors of kshv vil6 and human il6
US20120225933A1 (en)	2009-11-05	2012-09-06	Gonzalez Aseguinolaza Gloria	Regulated expression systems
EP2384761B1 (en) *	2010-05-07	2013-09-04	Deutsches Krebsforschungszentrum	Modified rodent parvovirus capable of propagating and spreading through human gliomas
US8663624B2 (en)	2010-10-06	2014-03-04	The Regents Of The University Of California	Adeno-associated virus virions with variant capsid and methods of use thereof
US10738326B2 (en)	2010-10-27	2020-08-11	Jichi Medical University	Adeno-associated virus vector for gene transfer to nervous system cells
HRP20220036T1 (hr)	2011-04-22	2022-04-01	The Regents Of The University Of California	Virioni adeno-povezanog virusa s varijantom kapsida i postupci njihove upotrebe
JP6385920B2 (ja)	2012-05-09	2018-09-05	オレゴンヘルスアンドサイエンスユニバーシティー	アデノ随伴ウイルスプラスミド及びベクター
US10294281B2 (en) *	2012-05-15	2019-05-21	University Of Florida Research Foundation, Incorporated	High-transduction-efficiency rAAV vectors, compositions, and methods of use
WO2013190059A1 (en)	2012-06-21	2013-12-27	Association Institut De Myologie	Widespread gene delivery of gene therapy vectors
CN105247044B (zh)	2013-05-31	2021-05-07	加利福尼亚大学董事会	腺相关病毒变体及其使用方法
KR20240090694A (ko) *	2013-07-22	2024-06-21	더 칠드런스 호스피탈 오브 필라델피아	변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
WO2015048534A1 (en)	2013-09-26	2015-04-02	University Of Florida Research Foundation, Inc.	Synthetic combinatorial aav capsid library for targeted gene therapy
EP3060669A1 (en)	2013-10-24	2016-08-31	uniQure IP B.V.	Aav-5 pseudotyped vector for gene therapy for neurological diseases
GB201403684D0 (en)	2014-03-03	2014-04-16	King S College London	Vector
CA2942776C (en)	2014-03-17	2023-01-24	Adverum Biotechnologies, Inc.	Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter
HUE054768T2 (hu) *	2014-05-02	2021-09-28	Genzyme Corp	AAV vektorok retina és CNS génterápiára
WO2015191508A1 (en)	2014-06-09	2015-12-17	Voyager Therapeutics, Inc.	Chimeric capsids
RU2020109343A (ru)	2014-11-05	2020-03-17	Вояджер Терапьютикс, Инк.	Полинуклеотиды aadc для лечения болезни паркинсона
RU2719192C2 (ru)	2014-11-14	2020-04-17	Вояджер Терапьютикс, Инк.	Модулирующие полинуклеотиды
CA2967367C (en)	2014-11-14	2023-05-16	Voyager Therapeutics, Inc.	Compositions and methods of treating amyotrophic lateral sclerosis (als)
EP4219742A1 (en)	2014-11-28	2023-08-02	uniQure IP B.V.	Dna impurities in a composition comprising a parvoviral virion
EP3230441A4 (en)	2014-12-12	2018-10-03	Voyager Therapeutics, Inc.	Compositions and methods for the production of scaav
SG11201707063TA (en)	2015-03-02	2017-09-28	Adverum Biotechnologies Inc	Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
JP6836999B2 (ja)	2015-03-24	2021-03-03	ザリージェンツオブザユニバーシティオブカリフォルニアＴｈｅＲｅｇｅｎｔｓＯｆＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＣａｌｉｆｏｒｎｉａ	アデノ随伴ウイルス変異体及びその使用方法
US10081659B2 (en)	2015-04-06	2018-09-25	The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services	Adeno-associated vectors for enhanced transduction and reduced immunogenicity
GB201508026D0 (en)	2015-05-11	2015-06-24	Ucl Business Plc	Capsid
DK3356390T3 (da)	2015-09-28	2021-04-12	Univ North Carolina Chapel Hill	Fremgangsmåder og sammensætninger til virusvektorer, der undgår antistoffer
EP3384035A4 (en)	2015-12-02	2019-08-07	Voyager Therapeutics, Inc.	ASSAYS FOR DETECTION OF NEUTRALIZING ANTIBODIES OF VAA
US11702672B2 (en)	2016-02-08	2023-07-18	University Of Iowa Research Foundation	Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US11684679B2 (en)	2016-03-07	2023-06-27	University Of Iowa Research Foundation	AAV-mediated expression using a synthetic promoter and enhancer
WO2017189959A1 (en)	2016-04-29	2017-11-02	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
WO2017189964A2 (en)	2016-04-29	2017-11-02	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
EP3452495B1 (en) *	2016-05-03	2021-06-23	Children's Medical Research Institute	Adeno-associated virus polynucleotides, polypeptides and virions
SG11201809684YA (en)	2016-05-13	2018-11-29	4D Molecular Therapeutics Inc	Adeno-associated virus variant capsids and methods of use thereof
CA3024448A1 (en)	2016-05-18	2017-11-23	Voyager Therapeutics, Inc.	Modulatory polynucleotides
CN109831916B (zh)	2016-05-18	2023-07-21	沃雅戈治疗公司	治疗亨廷顿氏舞蹈病的组合物和方法
KR102508820B1 (ko)	2016-07-29	2023-03-13	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	변이체 캡시드를 갖는 아데노-관련된 바이러스 비리온 및 이의 사용 방법
WO2018044933A1 (en)	2016-08-30	2018-03-08	The Regents Of The University Of California	Methods for biomedical targeting and delivery and devices and systems for practicing the same
AU2017345470B2 (en)	2016-10-19	2023-08-03	Adverum Biotechnologies, Inc.	Modified AAV capsids and uses thereof
WO2018132747A1 (en)	2017-01-13	2018-07-19	University Of Iowa Research Foundation	Bocaparvovirus small noncoding rna and uses thereof
WO2018139634A1 (ja)	2017-01-30	2018-08-02	学校法人日本医科大学	アデノ随伴ウイルス（ａａｖ）キャプシドタンパク質の変異体
WO2018144709A2 (en) *	2017-02-01	2018-08-09	The Trustees Of The University Of Pennsylvania	Gene therapy for treating citrullenemia
WO2018156654A1 (en)	2017-02-21	2018-08-30	University Of Florida Research Foundation, Incorporated	Modified aav capsid proteins and uses thereof
AU2018261790B2 (en)	2017-05-05	2024-10-03	Voyager Therapeutics, Inc.	Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
JP2020518259A (ja)	2017-05-05	2020-06-25	ボイジャーセラピューティクスインコーポレイテッドＶｏｙａｇｅｒＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ハンチントン病治療組成物および方法
JOP20190269A1 (ar)	2017-06-15	2019-11-20	Voyager Therapeutics Inc	بولي نوكليوتيدات aadc لعلاج مرض باركنسون
US11497576B2 (en)	2017-07-17	2022-11-15	Voyager Therapeutics, Inc.	Trajectory array guide system
EP3662060A2 (en)	2017-08-03	2020-06-10	Voyager Therapeutics, Inc.	Compositions and methods for delivery of aav
BR112020003571A2 (pt)	2017-08-28	2020-08-25	The Regents Of The University Of California	variantes capsidiais de vírus adenoassociado e métodos de uso das mesmas
MX2020003176A (es)	2017-09-20	2020-08-20	4D Molecular Therapeutics Inc	Variantes de capsides de virus adenoasociados y metodos de uso de estas.
CN111479924B (zh)	2017-10-16	2024-06-14	沃雅戈治疗公司	肌萎缩性侧索硬化症(als)的治疗
US20200237799A1 (en)	2017-10-16	2020-07-30	Voyager Therapeutics, Inc.	Treatment of amyotrophic lateral sclerosis (als)
JP7184894B2 (ja)	2017-11-27	2022-12-06	４ディーモレキュラーセラピューティクスインコーポレイテッド	アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用
US10538571B2 (en)	2017-11-27	2020-01-21	Coda Biotherapeutics, Inc.	Compositions and methods for neurological diseases
US10610606B2 (en)	2018-02-01	2020-04-07	Homology Medicines, Inc.	Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
WO2019161365A1 (en)	2018-02-19	2019-08-22	Homology Medicines, Inc.	Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
JP7098375B2 (ja) *	2018-03-26	2022-07-11	株式会社三共	スロットマシン
EP3773746A4 (en) *	2018-03-29	2022-01-19	University of Florida Research Foundation, Incorporated	VARIANTS OF AAV6
CN112004820B (zh) *	2018-03-30	2023-09-12	利兰斯坦福初级大学董事会	具有增强的人胰腺向性的新型重组腺相关病毒衣壳
CA3094465A1 (en)	2018-04-03	2019-10-10	Stridebio, Inc.	Virus vectors for targeting ophthalmic tissues
CN112272672A (zh)	2018-04-03	2021-01-26	斯特里迪比奥公司	抗体逃避性病毒载体
WO2019195444A1 (en)	2018-04-03	2019-10-10	Stridebio, Inc.	Antibody-evading virus vectors
CN112313331A (zh)	2018-04-27	2021-02-02	沃雅戈治疗公司	用于测量aadc病毒载体效力的方法
EP3793616A1 (en)	2018-05-15	2021-03-24	Voyager Therapeutics, Inc.	Compositions and methods for delivery of aav
KR20210019996A (ko)	2018-05-15	2021-02-23	보이저 테라퓨틱스, 인크.	파킨슨병의 치료를 위한 조성물 및 방법
WO2019222441A1 (en)	2018-05-16	2019-11-21	Voyager Therapeutics, Inc.	Aav serotypes for brain specific payload delivery
WO2019222444A2 (en)	2018-05-16	2019-11-21	Voyager Therapeutics, Inc.	Directed evolution
US12060567B2 (en)	2018-06-13	2024-08-13	Voyager Therapeutics, Inc.	Engineered untranslated regions (UTR) for AAV production
JP7152734B2 (ja) *	2018-06-28	2022-10-13	ネット株式会社	遊技機
US20210361318A1 (en)	2018-07-02	2021-11-25	Voyager Therapeutics, Inc.	Cannula system and use thereof
US20210254103A1 (en)	2018-07-02	2021-08-19	Voyager Therapeutics, Inc.	Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
SG11202100704PA (en)	2018-07-24	2021-02-25	Voyager Therapeutics Inc	Systems and methods for producing gene therapy formulations
WO2020028751A2 (en)	2018-08-03	2020-02-06	Voyager Therapeutics, Inc.	Aav variants with enhanced tropism
CA3111076A1 (en)	2018-08-30	2020-03-05	Tenaya Therapeutics, Inc.	Cardiac cell reprogramming with myocardin and ascl1
SG11202101819QA (en) *	2018-08-30	2021-03-30	Res Inst Nationwide Childrens Hospital	Gene therapy for the treatment of galactosemia
US20210395776A1 (en)	2018-09-28	2021-12-23	Voyager Therapeutics, Inc.	Frataxin expression constructs having engineered promoters and methods of use thereof
CA3115217A1 (en)	2018-10-02	2020-04-09	Voyager Therapeutics, Inc.	Redirection of tropism of aav capsids
TW202035689A (zh)	2018-10-04	2020-10-01	美商航海家醫療公司	測量病毒載體粒子的效價及強度之方法
CA3115248A1 (en)	2018-10-05	2020-04-09	Voyager Therapeutics, Inc.	Engineered nucleic acid constructs encoding aav production proteins
WO2020077165A1 (en)	2018-10-12	2020-04-16	Voyager Therapeutics, Inc.	Compositions and methods for delivery of aav
CA3116701A1 (en)	2018-10-15	2020-04-23	Voyager Therapeutics, Inc.	Expression vectors for large-scale production of raav in the baculovirus/sf9 system
MX2021008542A (es)	2019-01-18	2021-11-12	Voyager Therapeutics Inc	Métodos y sistemas para la producción de partículas de aav.
AU2020216480A1 (en)	2019-01-31	2021-09-09	Oregon Health & Science University	Methods for using transcription-dependent directed evolution of AAV capsids
JP2022521025A (ja)	2019-02-25	2022-04-04	ノバルティスアーゲー	Ｂｉｅｔｔｉクリスタリン網膜症を治療するための組成物及び方法
JP2022520875A (ja)	2019-02-25	2022-04-01	ノバルティスアーゲー	Ｂｉｅｔｔｉクリスタリン網膜症を治療するための組成物及び方法
CN113727992A (zh)	2019-03-21	2021-11-30	斯特里迪比奥公司	重组腺相关病毒载体
EP3947700A4 (en)	2019-04-01	2023-01-04	Tenaya Therapeutics, Inc.	ADENO-ASSOCIATED VIRUS WITH MANIPULATED CAPSID
WO2020223280A1 (en)	2019-04-29	2020-11-05	Voyager Therapeutics, Inc.	Aav variants with enhanced tropism
EP3962536A1 (en)	2019-04-29	2022-03-09	Voyager Therapeutics, Inc.	Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
EP3966227A1 (en)	2019-05-07	2022-03-16	Voyager Therapeutics, Inc.	Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
EP3997226A1 (en)	2019-07-11	2022-05-18	Tenaya Therapeutics, Inc.	Cardiac cell reprogramming with micrornas and other factors
US20220281922A1 (en)	2019-08-02	2022-09-08	Voyager Therapeutics, Inc.	Aav variants with enhanced tropism
US20220290182A1 (en)	2019-08-09	2022-09-15	Voyager Therapeutics, Inc.	Cell culture medium for use in producing gene therapy products in bioreactors
EP4022070A1 (en)	2019-08-26	2022-07-06	Voyager Therapeutics, Inc.	Controlled expression of viral proteins
WO2021046155A1 (en)	2019-09-03	2021-03-11	Voyager Therapeutics, Inc.	Vectorized editing of nucleic acids to correct overt mutations
JP2022550435A (ja)	2019-10-04	2022-12-01	ウルトラジェニックスファーマシューティカルインコーポレイテッド	組換えａａｖの改善された治療的使用のための方法
IL292297A (en)	2019-10-17	2022-06-01	Stridebio Inc	Adeno-associated viral vectors for the treatment of Niemann-Pick type c disease
TW202140791A (zh)	2020-01-13	2021-11-01	美商霍蒙拉奇醫藥公司	治療苯酮尿症之方法
WO2023172491A1 (en)	2022-03-07	2023-09-14	Ultragenyx Pharmaceutical Inc.	Modified batch aav production systems and methods
AU2021218703A1 (en)	2020-02-14	2022-07-28	Ultragenyx Pharmaceutical Inc.	Gene therapy for treating CDKL5 deficiency disorder
IL295989A (en)	2020-03-02	2022-10-01	Tenaya Therapeutics Inc	Gene vector control using cardiomyocyte expression microRNA
EP4121544A1 (en)	2020-03-19	2023-01-25	Ultragenyx Pharmaceutical Inc.	Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
US20230129893A1 (en)	2020-03-31	2023-04-27	Ultragenyx Pharmaceutical Inc.	Gene therapy for treating propionic acidemia
US20230131352A1 (en)	2020-04-01	2023-04-27	Voyager Therapeutics, Inc.	Redirection of tropism of aav capsids
BR112022020753A2 (pt)	2020-04-15	2022-12-20	Voyager Therapeutics Inc	Compostos de ligação a tau
GB202005732D0 (en)	2020-04-20	2020-06-03	Synpromics Ltd	Regulatory nucleic acid sequences
AU2021264081A1 (en) *	2020-05-01	2022-11-03	Trustees Of Boston College	Controlled modification of Adeno-Associated Virus (AAV) for enhanced gene therapy
IL298001A (en)	2020-05-13	2023-01-01	Voyager Therapeutics Inc	Redirecting tropism of adeno-associated virus capsids
TW202208632A (zh)	2020-05-27	2022-03-01	美商同源醫藥公司	用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
WO2021247995A2 (en)	2020-06-04	2021-12-09	Voyager Therapeutics, Inc.	Compositions and methods of treating neuropathic pain
WO2022026410A2 (en)	2020-07-27	2022-02-03	Voyager Therapeutics, Inc	Compositions and methods for the treatment of niemann-pick type c1 disease
CN117120619A (zh)	2020-07-27	2023-11-24	沃雅戈治疗公司	用于治疗与葡萄糖神经酰胺酶β缺陷相关的神经病症的组合物和方法
EP4192514A1 (en)	2020-08-06	2023-06-14	Voyager Therapeutics, Inc.	Cell culture medium for use in producing gene therapy products in bioreactors
CN113855794A (zh) *	2020-08-18	2021-12-31	深圳市俊元生物科技有限公司	一种基于棘突蛋白基因修饰干细胞的新型冠状病毒疫苗
CA3189878A1 (en)	2020-08-19	2022-02-24	Colin O'BANION	Adeno-associated virus vectors for treatment of rett syndrome
GB202013940D0 (en)	2020-09-04	2020-10-21	Synpromics Ltd	Regulatory nucleic acid sequences
US11781156B2 (en)	2020-10-09	2023-10-10	Tenaya Therapeutics, Inc.	Plakophillin-2 gene therapy methods and compositions
US20240141377A1 (en)	2021-03-03	2024-05-02	Voyager Therapeutics, Inc.	Controlled expression of viral proteins
WO2022187548A1 (en)	2021-03-03	2022-09-09	Voyager Therapeutics, Inc.	Controlled expression of viral proteins
KR20240014477A (ko)	2021-05-28	2024-02-01	상하이 레제네리드 테라피즈 컴퍼니 리미티드	변이체 캡시드를 갖는 재조합 아데노-연관 바이러스 및 이의 응용
CA3224488A1 (en)	2021-07-08	2023-01-12	Tenaya Therapeutics, Inc.	Optimized expression cassettes for gene therapy
WO2023019168A1 (en)	2021-08-11	2023-02-16	Ultragenyx Pharmaceutical Inc.	Compositions and methods for treating a muscular dystrophy
EP4405396A2 (en)	2021-09-20	2024-07-31	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
KR20240113624A (ko)	2021-11-02	2024-07-22	보이저 테라퓨틱스, 인크.	Aav 캡시드 변이체 및 이의 용도
EP4433169A1 (en)	2021-11-17	2024-09-25	Voyager Therapeutics, Inc.	Aav capsid variants and uses thereof
WO2023091949A2 (en)	2021-11-17	2023-05-25	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
TW202325850A (zh)	2021-11-29	2023-07-01	大陸商上海瑞宏迪醫藥有限公司	Aadc、gdnf多核苷酸及其用於治療帕金森病
WO2023111580A1 (en)	2021-12-16	2023-06-22	University Of Dundee	Targeted degradation of alpha-synuclein
WO2023133593A2 (en) *	2022-01-10	2023-07-13	University Of Florida Research Foundation, Incorporated	Aav5 capsid variants
WO2023147374A2 (en)	2022-01-25	2023-08-03	Voyager Therapeutics, Inc.	Baculovirus expression system
AU2023217698A1 (en)	2022-02-08	2024-07-25	Voyager Therapeutics, Inc.	Aav capsid variants and uses thereof
GB202201713D0 (en)	2022-02-10	2022-03-30	Univ Dundee	An affinity directed phosphatase system for targeted protein dephosphorylation
CN118660913A (zh)	2022-02-21	2024-09-17	上海瑞宏迪医药有限公司	Vegf结合分子及其医药用途
WO2023201207A1 (en)	2022-04-11	2023-10-19	Tenaya Therapeutics, Inc.	Adeno-associated virus with engineered capsid
WO2023212298A1 (en)	2022-04-29	2023-11-02	Broadwing Bio Llc	Bispecific antibodies and methods of treating ocular disease
WO2023212294A1 (en)	2022-04-29	2023-11-02	Broadwing Bio Llc	Angiopoietin-related protein 7-specific antibodies and uses thereof
WO2023212293A1 (en)	2022-04-29	2023-11-02	Broadwing Bio Llc	Complement factor h related 4-specific antibodies and uses thereof
WO2023220695A2 (en)	2022-05-13	2023-11-16	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
WO2023235791A1 (en)	2022-06-02	2023-12-07	Voyager Therapeutics, Inc.	Aav capsid variants and uses thereof
WO2023240236A1 (en)	2022-06-10	2023-12-14	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2023250388A1 (en)	2022-06-22	2023-12-28	Voyager Therapeutics, Inc.	Tau binding compounds
WO2024006741A1 (en)	2022-06-28	2024-01-04	Voyager Therapeutics, Inc.	Aav capsid variants and uses thereof
TW202424201A (zh)	2022-07-06	2024-06-16	美商航海家醫療公司	Ａａｖ殼體變異體及其用途
WO2024030976A2 (en)	2022-08-03	2024-02-08	Voyager Therapeutics, Inc.	Compositions and methods for crossing the blood brain barrier
WO2024054983A1 (en)	2022-09-08	2024-03-14	Voyager Therapeutics, Inc.	Controlled expression of viral proteins
TW202428602A (zh)	2022-09-15	2024-07-16	美商航海家醫療公司	Ｔａｕ結合化合物
WO2024145474A2 (en)	2022-12-29	2024-07-04	Voyager Therapeutics, Inc.	Compositions and methods for regulating mapt
WO2024163012A1 (en)	2023-02-02	2024-08-08	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2024215653A1 (en)	2023-04-10	2024-10-17	Tenaya Therapeutics, Inc.	Guide rnas, vectors, and virions for targeting mutations in the pln gene
WO2024215655A1 (en)	2023-04-10	2024-10-17	Tenaya Therapeutics, Inc.	Cardioprotective bag3 therapies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US116A (en)		1837-02-03		William croasdale
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US5225347A (en)	1989-09-25	1993-07-06	Innovir Laboratories, Inc.	Therapeutic ribozyme compositions and expression vectors
GB2276169A (en)	1990-07-05	1994-09-21	Celltech Ltd	Antibodies specific for carcinoembryonic antigen
US6001650A (en)	1995-08-03	1999-12-14	Avigen, Inc.	High-efficiency wild-type-free AAV helper functions
US6004797A (en)	1995-11-09	1999-12-21	Avigen, Inc.	Adenovirus helper-free recombinant AAV Virion production
US6177403B1 (en)	1996-10-21	2001-01-23	The Trustees Of The University Of Pennsylvania	Compositions, methods, and apparatus for delivery of a macromolecular assembly to an extravascular tissue of an animal
US6093392A (en)	1997-03-14	2000-07-25	Childrens Hospital Of Phildelphia	Methods and compositions for use in gene therapy for treatment of hemophilia
US6156303A (en)	1997-06-11	2000-12-05	University Of Washington	Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
AU780231B2 (en)	1998-11-10	2005-03-10	University Of North Carolina At Chapel Hill, The	Virus vectors and methods of making and administering the same
US6498244B1 (en)	1999-05-28	2002-12-24	Cell Genesys, Inc.	Adeno-associated virus capsid immunologic determinants
AU2001257611A1 (en)	2000-04-28	2001-11-12	Avigen, Inc.	Polynucleotides for use in recombinant adeno-associated virus virion production
US6962815B2 (en) *	2001-01-05	2005-11-08	Children's Hopital Inc.	AAV2 vectors and methods
ES2455126T3 (es) *	2001-11-13	2014-04-14	The Trustees Of The University Of Pennsylvania	Secuencias Cy.5 de virus adeno-asociados (AAV), vectores que las contienen y uso de las mismas.
AU2003221733A1 (en) *	2002-04-17	2003-11-03	University Of Florida Research Foundation, Inc.	Improved raav vectors
DK3235827T3 (da)	2003-06-19	2021-04-19	Genzyme Corp	Aav-virioner med reduceret immunreaktivitet og anvendelser deraf

2004
- 2004-06-21 DK DK17162137.8T patent/DK3235827T3/da active
- 2004-06-21 PT PT47558002T patent/PT1633772E/pt unknown
- 2004-06-21 PL PL11158742T patent/PL2357189T3/pl unknown
- 2004-06-21 ES ES13163168.1T patent/ES2629087T3/es not_active Expired - Lifetime
- 2004-06-21 ES ES11158742.4T patent/ES2627913T3/es not_active Expired - Lifetime
- 2004-06-21 PL PL17162137T patent/PL3235827T3/pl unknown
- 2004-06-21 ES ES17162137T patent/ES2862206T3/es not_active Expired - Lifetime
- 2004-06-21 SI SI200432395A patent/SI2657248T1/sl unknown
- 2004-06-21 DK DK11158742.4T patent/DK2357189T3/en active
- 2004-06-21 ES ES04755800.2T patent/ES2563064T3/es not_active Expired - Lifetime
- 2004-06-21 HU HUE17162137A patent/HUE054046T2/hu unknown
- 2004-06-21 HU HUE04755800A patent/HUE029556T2/en unknown
- 2004-06-21 PT PT111587424T patent/PT2357189T/pt unknown
- 2004-06-21 PT PT131631681T patent/PT2657247T/pt unknown
- 2004-06-21 EP EP11158742.4A patent/EP2357189B1/en not_active Expired - Lifetime
- 2004-06-21 PL PL04755800.2T patent/PL1633772T3/pl unknown
- 2004-06-21 PL PL13163182T patent/PL2657248T3/pl unknown
- 2004-06-21 HU HUE11158742A patent/HUE034546T2/en unknown
- 2004-06-21 EP EP13163182.2A patent/EP2657248B1/en not_active Expired - Lifetime
- 2004-06-21 PL PL13163168T patent/PL2657247T3/pl unknown
- 2004-06-21 SI SI200432393A patent/SI2357189T1/sl unknown
- 2004-06-21 WO PCT/US2004/019884 patent/WO2004112727A2/en active Application Filing
- 2004-06-21 PT PT131631822T patent/PT2657248T/pt unknown
- 2004-06-21 JP JP2006517511A patent/JP2007524386A/ja active Pending
- 2004-06-21 EP EP13163168.1A patent/EP2657247B1/en not_active Expired - Lifetime
- 2004-06-21 SI SI200432300A patent/SI1633772T1/sl unknown
- 2004-06-21 DK DK13163168.1T patent/DK2657247T3/en active
- 2004-06-21 HU HUE13163168A patent/HUE034785T2/en unknown
- 2004-06-21 DK DK13163182.2T patent/DK2657248T3/en active
- 2004-06-21 PT PT171621378T patent/PT3235827T/pt unknown
- 2004-06-21 EP EP04755800.2A patent/EP1633772B1/en not_active Expired - Lifetime
- 2004-06-21 US US10/873,632 patent/US7259151B2/en not_active Expired - Lifetime
- 2004-06-21 HU HUE13163182A patent/HUE034597T2/en unknown
- 2004-06-21 ES ES13163182T patent/ES2629380T3/es not_active Expired - Lifetime
- 2004-06-21 SI SI200432399A patent/SI2657247T1/sl unknown
- 2004-06-21 SI SI200432509T patent/SI3235827T1/sl unknown
- 2004-06-21 DK DK04755800.2T patent/DK1633772T3/en active
- 2004-06-21 EP EP17162137.8A patent/EP3235827B1/en not_active Expired - Lifetime
2007
- 2007-07-09 US US11/825,798 patent/US9506083B2/en not_active Expired - Lifetime
2010
- 2010-09-01 JP JP2010196261A patent/JP5551029B2/ja not_active Expired - Lifetime
2013
- 2013-09-02 JP JP2013181091A patent/JP2014057579A/ja not_active Withdrawn
2016
- 2016-02-04 JP JP2016019562A patent/JP2016084362A/ja not_active Withdrawn
- 2016-02-16 CY CY20161100126T patent/CY1117575T1/el unknown
- 2016-10-18 US US15/296,817 patent/US20170232117A1/en not_active Abandoned
2017
- 2017-06-08 CY CY20171100603T patent/CY1119222T1/el unknown
- 2017-06-21 CY CY20171100650T patent/CY1119241T1/el unknown
- 2017-06-21 CY CY20171100649T patent/CY1119279T1/el unknown
- 2017-11-02 JP JP2017212654A patent/JP6759177B2/ja not_active Expired - Lifetime
- 2017-12-07 US US15/835,188 patent/US20180280540A1/en not_active Abandoned
2019
- 2019-01-29 US US16/261,424 patent/US11083800B2/en not_active Expired - Lifetime
2020
- 2020-03-03 JP JP2020035975A patent/JP2020096642A/ja not_active Withdrawn
2021
- 2021-04-13 CY CY20211100317T patent/CY1124371T1/el unknown
- 2021-06-23 US US17/356,176 patent/US20220016264A1/en not_active Abandoned
2023
- 2023-05-17 JP JP2023081558A patent/JP2023106497A/ja active Pending

Also Published As

Publication number	Publication date
DK2657247T3 (en)	2017-07-10
DK2357189T3 (en)	2017-06-19
EP2657248A1 (en)	2013-10-30
US20080008690A1 (en)	2008-01-10
US9506083B2 (en)	2016-11-29
EP3235827A2 (en)	2017-10-25
EP2357189B1 (en)	2017-03-08
PL2657247T3 (pl)	2017-09-29
US20220016264A1 (en)	2022-01-20
JP2010273690A (ja)	2010-12-09
JP2018029614A (ja)	2018-03-01
JP6759177B2 (ja)	2020-09-23
CY1119222T1 (el)	2018-02-14
ES2629380T3 (es)	2017-08-09
HUE029556T2 (en)	2017-03-28
ES2629087T3 (es)	2017-08-07
US20190314526A1 (en)	2019-10-17
PL3235827T3 (pl)	2021-07-05
HUE054046T2 (hu)	2021-08-30
PT2357189T (pt)	2017-06-20
CY1124371T1 (el)	2022-07-22
SI1633772T1 (sl)	2016-06-30
PT2657248T (pt)	2017-06-26
EP2657247A1 (en)	2013-10-30
PL1633772T3 (pl)	2016-10-31
SI3235827T1 (sl)	2021-05-31
SI2657248T1 (sl)	2017-07-31
ES2862206T3 (es)	2021-10-07
ES2563064T3 (es)	2016-03-10
ES2627913T3 (es)	2017-08-01
EP1633772B1 (en)	2015-11-18
PT2657247T (pt)	2017-06-29
PT3235827T (pt)	2021-04-09
US11083800B2 (en)	2021-08-10
HUE034546T2 (en)	2018-02-28
WO2004112727A2 (en)	2004-12-29
US20060051333A1 (en)	2006-03-09
PT1633772E (pt)	2016-03-22
EP1633772A4 (en)	2008-08-27
EP2357189A2 (en)	2011-08-17
JP5551029B2 (ja)	2014-07-16
JP2023106497A (ja)	2023-08-01
SI2657247T1 (sl)	2017-07-31
CY1119241T1 (el)	2018-02-14
US20170232117A1 (en)	2017-08-17
US7259151B2 (en)	2007-08-21
PL2357189T3 (pl)	2017-08-31
EP2657248B1 (en)	2017-03-22
EP2357189A3 (en)	2011-11-16
DK2657248T3 (en)	2017-06-26
DK1633772T3 (en)	2016-02-29
US20180280540A1 (en)	2018-10-04
SI2357189T1 (sl)	2017-07-31
DK3235827T3 (da)	2021-04-19
JP2016084362A (ja)	2016-05-19
HUE034597T2 (en)	2018-02-28
EP1633772A2 (en)	2006-03-15
HUE034785T2 (en)	2018-02-28
EP3235827B1 (en)	2021-01-13
EP2657247B1 (en)	2017-03-22
EP3235827A3 (en)	2017-12-20
CY1117575T1 (el)	2017-04-26
JP2007524386A (ja)	2007-08-30
JP2014057579A (ja)	2014-04-03
JP2020096642A (ja)	2020-06-25
CY1119279T1 (el)	2018-02-14
WO2004112727A3 (en)	2005-05-06

Publication	Publication Date	Title
SI1633772T1 (sl)	2016-06-30	AAV virioni z zmanjšano imunoreaktivnostjo in uporaba za ta namen
EP1678423A4 (en)	2010-12-22	MICRO PUMP
TWI348890B (en)	2011-09-21	Mixtures comprising strobilurins and ethylene modulators
HK1091132A1 (en)	2007-01-12	Anti-cd33 antibodies and the use thereof -cd33
GB0308732D0 (en)	2003-05-21	Absorption enhancers
SG118214A1 (en)	2006-01-27	Resistor with reduced leakage
TWI367222B (en)	2012-07-01	Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof
EP1596756A4 (en)	2009-11-11	MEANS TO INCREASE ABSORPTION
GB2401084B (en)	2006-08-16	Disposable printer
IL169322A0 (en)	2007-07-04	Hcv combination therapy
GB2390109B (en)	2005-01-05	Nonstructural buoyancy can
GB2400812B (en)	2006-02-22	Handle structure
EP1660088A4 (en)	2009-04-29	PYRIDOMORPHINANES, PYRIDAZINOMORPHINANES AND USE THEREOF
GB0329247D0 (en)	2004-01-21	Compounds and inks
EP1615552A4 (en)	2006-11-29	SAPHIRINS AND CORRESPONDING USES
TW584241U (en)	2004-04-11	Detachable compact keyboard and the application structure
TW592199U (en)	2004-06-11	Vessel with improved structure
GB2408484B (en)	2006-08-16	Mailer
HK1057445A2 (en)	2004-03-05	Chinese ink-box
GB0314212D0 (en)	2003-07-23	Eneuresis bleep
GB0301602D0 (en)	2003-02-26	Multi-plug
AU153396S (en)	2003-10-22	Childroof stopper
GB0300277D0 (en)	2003-02-05	Conventional hand unit-keyboard
GB0316484D0 (en)	2003-08-20	Sailing
AU153034S (en)	2003-09-11	Hatbox with lid